Literature DB >> 17347915

Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

C M Eng1, J Fletcher, W R Wilcox, S Waldek, C R Scott, D O Sillence, F Breunig, J Charrow, D P Germain, K Nicholls, M Banikazemi.   

Abstract

The Fabry Registry is a global observational research platform established to define outcome data on the natural and treated course of this rare disorder. Participating physicians submit structured longitudinal data to a centralized, confidential database. This report describes the baseline demographic and clinical characteristics of the first 1765 patients (54% males (16% aged < 20 years) and 46% females (13% < 20 years)) enrolled in the Fabry Registry. The median ages at symptom onset and diagnosis were 9 and 23 years (males) and 13 and 32 years (females), respectively, indicating diagnostic delays in both sexes. Frequent presenting symptoms in males included neurological pain (62%), skin signs (31%), gastroenterological symptoms (19%), renal signs (unspecified) (17%), and ophthalmological signs (11%). First symptoms in females included neurological pain (41%), gastroenterological symptoms (13%), ophthalmological (12%), and skin signs (12%). For those patients reporting renal progression, the median age at occurrence was 38 years for both sexes, but onset of cerebrovascular and cardiovascular events was later in females (median 43 and 47 years, respectively) than in males (38 and 41 years, respectively). This paper demonstrates that in spite of the considerable burden of disease in both sexes that begins to manifest in childhood or adolescence, the recognition of the underlying diagnosis is delayed by 14 years in males and 19 years in females. The Fabry Registry provides data that can increase awareness of common symptoms in all age groups, as well as insight into treated and untreated disease course, leading to improved recognition and earlier treatment, and possibly to improved outcomes for affected individuals.

Entities:  

Mesh:

Year:  2007        PMID: 17347915     DOI: 10.1007/s10545-007-0521-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  27 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

3.  Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Authors:  R Schiffmann; G J Murray; D Treco; P Daniel; M Sellos-Moura; M Myers; J M Quirk; G C Zirzow; M Borowski; K Loveday; T Anderson; F Gillespie; K L Oliver; N O Jeffries; E Doo; T J Liang; C Kreps; K Gunter; K Frei; K Crutchfield; R F Selden; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Gastrointestinal structure and function in Fabry's disease.

Authors:  K J Sheth; S L Werlin; M E Freeman; A E Hodach
Journal:  Am J Gastroenterol       Date:  1981-09       Impact factor: 10.864

Review 5.  Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.

Authors:  Robert J Desnick; Roscoe Brady; John Barranger; Allan J Collins; Dominique P Germain; Martin Goldman; Gregory Grabowski; Seymour Packman; William R Wilcox
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

6.  The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients.

Authors:  S H Morgan; P Rudge; S J Smith; A M Bronstein; B E Kendall; E Holly; E P Young; M D Crawfurd; R Bannister
Journal:  Q J Med       Date:  1990-05

7.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

8.  Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.

Authors:  Beth L Thurberg; H Randolph Byers; Scott R Granter; Robert G Phelps; Ronald E Gordon; Michael O'Callaghan
Journal:  J Invest Dermatol       Date:  2004-04       Impact factor: 8.551

9.  Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

Authors:  William R Wilcox; Maryam Banikazemi; Nathalie Guffon; Stephen Waldek; Philip Lee; Gabor E Linthorst; Robert J Desnick; Dominique P Germain
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

Review 10.  Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.

Authors:  Christine M Eng; Dominique P Germain; Maryam Banikazemi; David G Warnock; Christoph Wanner; Robert J Hopkin; Jan Bultas; Philip Lee; Katherine Sims; Scott E Brodie; Gregory M Pastores; Joerg M Strotmann; William R Wilcox
Journal:  Genet Med       Date:  2006-09       Impact factor: 8.822

View more
  87 in total

Review 1.  [Lysosomal storage diseases].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 2.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

3.  Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity.

Authors:  Justina C Wu; Carolyn Y Ho; Hicham Skali; Rekha Abichandani; William R Wilcox; Maryam Banikazemi; Seymour Packman; Katherine Sims; Scott D Solomon
Journal:  Eur Heart J       Date:  2010-01-07       Impact factor: 29.983

4.  An automated communication system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants.

Authors:  R L Richesson; H S Lee; D Cuthbertson; J Lloyd; K Young; J P Krischer
Journal:  Contemp Clin Trials       Date:  2008-09-07       Impact factor: 2.226

5.  Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.

Authors:  William R Wilcox; Ulla Feldt-Rasmussen; Ana Maria Martins; Alberto Ortiz; Roberta M Lemay; Ana Jovanovic; Dominique P Germain; Carmen Varas; Katherine Nicholls; Frank Weidemann; Robert J Hopkin
Journal:  JIMD Rep       Date:  2017-05-17

Review 6.  Assessment of renal pathology and dysfunction in children with Fabry disease.

Authors:  Uma Ramaswami; Behzad Najafian; Arrigo Schieppati; Michael Mauer; Daniel G Bichet
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

7.  Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.

Authors:  Alessandro Salviati; Alessandro P Burlina; Walter Borsini
Journal:  Neurol Sci       Date:  2010-03-19       Impact factor: 3.307

8.  Early diagnosis of fabry disease in a patient with toe tip pain.

Authors:  Ki Bum Park; Kyung Ream Han; Jae Woo Lee; Seung Ho Kim; Do Wan Kim; Chan Kim; Jung Min Ko
Journal:  Korean J Pain       Date:  2010-08-26

Review 9.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

10.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.